Overview

Efficacy of AJOVY (Fremanezumab-vfrm) on Interictal Migraine Related Burden

Status:
Recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
This study is being conducted to evaluate the efficacy and safety of AJOVY (fremanezumab-vfrm) on interictal migraine related burden in adults.
Phase:
Phase 4
Details
Lead Sponsor:
David True
Treatments:
Antibodies, Monoclonal
Erenumab